Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) had its target price upped by Needham & Company LLC from $150.00 to $162.00 in a research note issued to investors on Friday morning, The Fly reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other research firms have also commented on SRPT. Credit Suisse Group dropped their price target on Sarepta Therapeutics from $95.00 to $90.00 and set a neutral rating on the stock in a research report on Friday, June 24th. Cantor Fitzgerald decreased their price target on Sarepta Therapeutics from $140.00 to $128.00 and set an overweight rating for the company in a research note on Friday, June 24th. Morgan Stanley reduced their target price on Sarepta Therapeutics from $77.00 to $74.00 and set an equal weight rating for the company in a research note on Thursday, May 19th. The Goldman Sachs Group dropped their price target on Sarepta Therapeutics from $181.00 to $155.00 and set a buy rating for the company in a report on Tuesday, May 24th. Finally, StockNews.com cut Sarepta Therapeutics from a buy rating to a hold rating in a report on Saturday, May 21st. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $120.25.
Sarepta Therapeutics Trading Up 8.2 %
NASDAQ:SRPT opened at $92.95 on Friday. Sarepta Therapeutics has a 1-year low of $61.28 and a 1-year high of $101.24. The business’s 50-day moving average price is $75.54 and its two-hundred day moving average price is $75.66. The company has a current ratio of 5.56, a quick ratio of 5.13 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $8.13 billion, a price-to-earnings ratio of -21.92 and a beta of 1.22.
Institutional Investors Weigh In On Sarepta Therapeutics
A number of institutional investors have recently made changes to their positions in SRPT. Exchange Traded Concepts LLC grew its position in shares of Sarepta Therapeutics by 191.7% in the 2nd quarter. Exchange Traded Concepts LLC now owns 633 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 416 shares during the last quarter. IndexIQ Advisors LLC bought a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at about $61,000. UMB Bank N A MO bought a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at about $69,000. KRS Capital Management LLC bought a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at about $96,000. Finally, Laurel Wealth Planning LLC bought a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at about $117,000. Institutional investors own 81.43% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.